2021. Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial. SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s18. DOI:https://doi.org/10.25251/skin.5.supp.18.